Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction
Corresponding Author
E. Raschi
Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Correspondence: E. Raschi. E-mail: [email protected]
Search for more papers by this authorF. Salvo
University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team Pharmacoepidemiology, UMR 1219, Bordeaux, France
CHU de Bordeaux, Pôle de santé Publique, Service de Pharmacologie Médicale, Bordeaux, France
Search for more papers by this authorM. La Placa
Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Search for more papers by this authorE. Poluzzi
Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Search for more papers by this authorF. De Ponti
Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Search for more papers by this authorCorresponding Author
E. Raschi
Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Correspondence: E. Raschi. E-mail: [email protected]
Search for more papers by this authorF. Salvo
University of Bordeaux, Inserm, Bordeaux Population Health Research Center, team Pharmacoepidemiology, UMR 1219, Bordeaux, France
CHU de Bordeaux, Pôle de santé Publique, Service de Pharmacologie Médicale, Bordeaux, France
Search for more papers by this authorM. La Placa
Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Search for more papers by this authorE. Poluzzi
Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Search for more papers by this authorF. De Ponti
Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
Search for more papers by this authorAbstract
Linked article: M.A. Gupta et al. J Eur Acad Dermatol Venereol 2020;34: e431–e432. https://doi.org/10.1111/jdv.16378.
References
- 1Gupta MA, Sheridan AD, Gupta AK. Reduced risk of suicidal behaviors associated with the treatment of hidradenitis suppurativa with tumor necrosis factor (TNF) alpha antagonists: results from the US FDA Adverse Events Reporting System (FAERS) pharmacovigilance database. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16224. [Epub ahead of print].
- 2Patel KR, Lee HH, Rastogi S et al. Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol 2019. https://doi.org/10.1016/j.jaad.2019.11.068. [Epub ahead of print].
- 3Minnema LA, Giezen TJ, Souverein PC, Egberts TCG, Leufkens HGM, Gardarsdottir H. Exploring the association between monoclonal antibodies and depression and suicidal ideation and behavior: a VigiBase study. Drug Saf 2019; 42: 887–895.
- 4Raschi E, Poluzzi E, De Ponti F. Reduced neuropsychiatric events as "beneficial reactions" to drugs: seek associations with caution. Brain Behav Immun 2020; 84: 275–276.
- 5Raschi E, Poluzzi E, Salvo F et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous. Nutr Metab Cardiovsc Dis 2018; 28: 533–542.
- 6Araujo AGS, Borba HHL, Tonin FS et al. Safety of biologics approved for the treatment of rheumatoid arthritis and other autoimmune diseases: a disproportionality analysis from the FDA Adverse Event Reporting System (FAERS). BioDrugs 2018; 32: 377–390.
- 7Arnaud M, Salvo F, Ahmed I et al. A method for the minimization of competition bias in signal detection from spontaneous reporting databases. Drug Saf 2016; 39: 251–260.
- 8Roman M, Irwin MR. Novel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far. Brain Behav Immun 2020; 83: 7–21.
- 9Bavaresco DV, Uggioni MLR, Ferraz SD et al. Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis. Pharmacol Biochem Behav 2020; 188: 172838.
- 10Savage KT, Gonzalez Brant E, Flood KS, Salian P, Porter ML, Kimball AB. Publication trends in hidradenitis suppurativa from 2008–2018. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16213. [Epub ahead of print].
10.1111/jdv.16213 Google Scholar
Citing Literature
